The resignation of Food and Drug Administration (FDA) commissioner Scott Gottlieb adds further uncertainty to the future of federal oversight of CBD in the US
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.